课题基金 / 基金详情

Home-based Autologous Hematopoietic Stem Cell Transplantation to Improve Outcomes and Decrease Costs

Home-based Autologous Hematopoietic Stem Cell Transplantation to Improve Outcomes and Decrease Costs
家庭自体造血干细胞移植可改善结果并降低成本
批准号:
10368106
负责人:
Anthony Sung
金额:
$62.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-06-01 至 2026-03-31

项目摘要

项目成果

Anthony Sung的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Physical, emotional, and financial burdens are especially demanding for older cancer patients undergoing autologous hematopoietic stem cell transplant (HCT), which requires prolonged hospitalizations or daily visits in outpatient clinics for 3-4 weeks and caregivers to be available 24/7. Home HCT is a novel strategy that provides intensive support, integrated care management, and individualized interventions focused on helping patients and caregivers manage care at home, with the potential to improve patient quality of life, reduce caregiver strain, and decrease healthcare utilization and costs. Building on our successful phase 1 home HCT pilot, we propose a randomized phase 2 trial of home vs. standard autologous HCT. In contrast to standard hospital-based care, providers of home HCT make daily house calls, working with patients and caregivers to form individualized treatment plans that facilitate management of HCT complications at home. Home-based care may have many advantages, particularly for older adults, and home HCT may result in better patient quality of life (remaining in their normal environment), better activity (easier to walk around the home or neighborhood than crowded hospital corridors), better nutrition (home vs. hospital food), better sleep (home vs. hospital bed), etc. Additionally, logistics are vastly simplified for caregivers who don’t need to drive back-and-forth daily, which could decrease caregiver strain, anxiety, and fatigue, thereby improving caregiver quality of life; in addition, this may free caregivers to provide more support for patients, further improving patient outcomes. In addition, increased confidence and ability to take care of patients at home may reduce emergency room visits and readmissions. Though upfront staffing costs may be higher, overall health system costs may be lowered by reducing complications and keeping patients out of the hospital. Our first aim is to determine the impact of home HCT on patient health, quality of life and function, including overall quality of life (FACT-BMT, primary endpoint), symptoms, physical function, cognitive function, fatigue, sleep, nutritional status, mental health, social support, self-efficacy, out-of-pocket costs, and return to work. Our second aim is to determine the impact of home HCT on caregiver well-being, including many of the above measures as well as caregiver strain (caregiver strain index, primary endpoint), burden, and satisfaction. Qualitative studies are part of both aims to better understand which aspects of home HCT are most impactful and may be applied to other diseases; this is especially important for planning future studies and implementation. The third aim is to determine the effect home HCT on healthcare utilization outcomes such as readmissions, length of stay, and overall costs. The long-term objectives are to improve outcomes for patients and caregivers by supporting their care at home; keeping patients at home and out of the hospital may in turn reduce costs. The success of this study may serve as a model for other strategies to reduce caregiver burden and keep patients out of the hospital by delivering quality care at home.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hematopoietic Stem Cell Transplantation Combined with CSF1 Inhibition to Attenuate the Pathogenesis of Alzheimer's Disease
  • 批准号:
    10318999
  • 项目类别:
  • 资助金额:
    $16.1万
  • 财政年份:
    2021
  • 负责人:
    Anthony Sung
  • 依托单位:
Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation
  • 批准号:
    10452599
  • 项目类别:
  • 资助金额:
    $36.23万
  • 财政年份:
    2020
  • 负责人:
    Anthony Sung
  • 依托单位:
Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation
  • 批准号:
    10662270
  • 项目类别:
  • 资助金额:
    $36.23万
  • 财政年份:
    2020
  • 负责人:
    Anthony Sung
  • 依托单位:
Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation
  • 批准号:
    10202731
  • 项目类别:
  • 资助金额:
    $36.23万
  • 财政年份:
    2020
  • 负责人:
    Anthony Sung
  • 依托单位:
海外基金